Clinical Trial Update: Clinical Trial to Evaluate the Tolerance of TQB2210 Injection [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 clinical trial evaluating the tolerance of TQB2210 Injection in patients with advanced malignant tumours.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• TQB2210 Injection (TQB2210)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: Advanced Malignant Tumours | Phase 1 | Status: COMPLETED